Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Pulmonary Arterial Hypertension

    Current Location

    Search
    Pulmonary Arterial Hypertension
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Pulmonary Hypertension Clinical Trials

    46 Hypertension Trials near Houston, TX

    54 Hypertension Trials near Olathe, KS

    39 Hypertension Trials near Overland Park, KS

    36 Hypertension Trials near Columbus, OH

    Top Pulmonary Embolism Clinical Trials

    Top Pulmonary Fibrosis Clinical Trials

    Top Idiopathic Pulmonary Fibrosis Clinical Trials

    Top Chronic Obstructive Pulmonary Disease Clinical Trials

    Top Hypertension Clinical Trials

    Top Idiopathic Intracranial Hypertension Clinical Trials

    Top Hypertension Clinical Trials near Akron, OH

    By Trial

    Ralinepag for Pulmonary Arterial Hypertension

    Macitentan for Pulmonary Hypertension

    Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

    DHEA for Pulmonary Hypertension

    Pulmonary Artery Denervation for Pulmonary Hypertension

    Metformin + mHealth for Pulmonary Arterial Hypertension

    Ralinepag for Pulmonary Arterial Hypertension

    High-Dose Macitentan for PAH

    Blood Pressure Cuffs for Hypertension in Pregnancy

    Symphony Thrombectomy for Pulmonary Embolism

    Intra-arterial Chemotherapy for Retinoblastoma

    Oxygen Saturation Target for Newborn Pulmonary Hypertension

    Related Searches

    Top Aortic-stenosis Clinical Trials

    Top Schizophrenia Clinical Trials

    MultiStem for Trauma-Induced Multiple Organ Failure

    Durvalumab + Tremelimumab for Non-Small Cell Lung Cancer

    Ketone Monoester for Hormonal Imbalance After Resistance Training

    SPARS Rehabilitation Program for Rotator Cuff Injury

    Brain Stimulation for Mild Cognitive Impairment

    Oral Carbon Monoxide Therapy for Sickle Cell Anemia

    Soquelitinib for Peripheral T-Cell Lymphoma

    Venetoclax + Daratumumab + Dexamethasone for Amyloidosis

    Evolocumab + Immunotherapy for Lung Cancer

    Saline Infusion for POTS

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Clear All

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      38 Pulmonary Arterial Hypertension Trials Near You

      Power is an online platform that helps thousands of Pulmonary Arterial Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Seralutinib for Pulmonary Arterial Hypertension

      Falls Church, Virginia
      This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Medical Abnormality, Others
      Must Be Taking:Seralutinib

      300 Participants Needed

      Seralutinib for Pulmonary Arterial Hypertension

      Falls Church, Virginia
      This trial is testing a medication called seralutinib to see if it can help people with a specific type of lung disease (PAH) improve their ability to exercise. The medication works by blocking signals that cause the blood vessels in the lungs to tighten and narrow. Seralutinib is delivered via inhalation and is being developed for patients with pulmonary arterial hypertension. The goal is to see if this can reduce lung pressure and delay worsening of the disease.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis, Hypertension, Others
      Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors

      350 Participants Needed

      Spironolactone for Pulmonary Arterial Hypertension

      Bethesda, Maryland
      Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as inflammation, leading to worsening of the disease. A drug called spironolactone has been known to improve blood vessel function and reduce inflammation. Some people with PAH take spironolactone to help treat fluid retention. However, its effect on inflammation and blood vessel function in patients with PAH is not known. Researchers want to see if spironolactone can help these conditions in people with PAH. Objectives: - To test the effectiveness of spironolactone in treating pulmonary arterial hypertension. Eligibility: - Individuals at least 18 years of age with pulmonary arterial hypertension. Design: * This study will last for 24 weeks. Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will take either spironolactone or a placebo. They will take their study drug or placebo for 7 weeks. Treatment will be monitored with regular blood tests. * In Week 8, participants who have had no reaction to the treatment will receive a higher dose of the drug or placebo. * In Week 12, participants will have a study visit with heart and lung function tests. They will also have a 6-minute walk test, and provide blood and urine samples. * After additional study visits for blood samples, participants will have a final visit in Week 24. The tests from Week 12 will be repeated at this visit.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Right Heart Failure, Cirrhosis, Active Infection, Others
      Must Not Be Taking:Spironolactone, Eplerenone, ACE Inhibitors, ARBs

      70 Participants Needed

      Intravenous ZMA001 for Pulmonary Arterial Hypertension

      Bethesda, Maryland
      Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people. Objective: To test a drug (ZMA001) in healthy volunteers. Eligibility: Healthy adults aged 18 to 60 years. Design: Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function. Participants will come to the clinic for 1 inpatient visit of up to 48 hours. ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting. After a screening visit, participants will have 1 inpatient visit and up to 6 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long. This study is the first time ZMA001 will be administered to people.

      Trial Details

      Trial Status:Recruiting
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:HIV, Drug Use, Alcohol Abuse, Others
      Must Not Be Taking:Herbal Supplements

      96 Participants Needed

      MRI-Guided Catheterization for Heart Disease

      Bethesda, Maryland
      Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers. Magnetic resonance imaging (MRI) fluoroscopy shows continuous pictures of the heart chambers that doctors can watch while they work. Researchers want to test this procedure with catheterization tools routinely used in x-ray catheterization called guidewires. Guidewires will help move the heart catheter through the different heart chambers. Guidewires are usually considered unsafe during MRI because MRI can cause a guidewire to heat while inside the blood vessels and heart. Researchers are testing special low energy MRI settings that allow certain guidewires to be used during MRI catheterization without heating. Using these guidewires during MRI may help to decrease the amount of time you are in the MRI scanner, and the overall time the MRI catheterization procedure takes. Objectives: To test if certain MRI settings make it safe to use a guidewire during MRI fluoroscopy. Eligibility: Adults 18 and older whose doctors have recommended right heart catheterization. Design: Researchers will screen participants by reviewing their lab results and questionnaire answers. Participants may give 4 blood samples. Participants will be sedated. They will have a tube (catheter) placed in the groin, arm, or neck if they don t already have one. Patches on the skin will monitor heart rhythm. Special antennas, covered in pads, will be placed against the body. Participants will lie flat on a table that slides in and out of the MRI scanner as it makes pictures. Participants will get earplugs for the loud knocking noise. They can talk on an intercom. They will be inside the scanner for up to 2 hours. They can ask to stop at any time. During a heart catheterization, catheters will be inserted through the tubes already in place. The catheters are guided by MRI fluoroscopy into the chambers of the heart and vessels. The guidewire will help position the catheter.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      100 Participants Needed

      Inhaled Treprostinil for Pulmonary Arterial Hypertension

      Falls Church, Virginia
      The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Lung Transplant, Others

      92 Participants Needed

      Macitentan for Pulmonary Hypertension

      Washington, District of Columbia
      This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:1 - 17

      Key Eligibility Criteria

      Disqualifiers:Portal Hypertension, Eisenmenger Syndrome, Others
      Must Not Be Taking:IV Prostanoids

      165 Participants Needed

      Sotatercept for Pulmonary Arterial Hypertension

      Washington, District of Columbia
      This trial is testing sotatercept, a medication for high blood pressure in the lungs, in adults with PAH who have completed earlier studies. It aims to see if the medication is safe and effective over a long period. Sotatercept helps lung blood vessels function better, reducing lung pressure. Sotatercept has shown promising results in earlier studies for reducing lung pressure and improving exercise tolerance in patients with pulmonary arterial hypertension (PAH).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Missed Doses, Others
      Must Be Taking:PAH Therapy

      815 Participants Needed

      Sotatercept for Pulmonary Arterial Hypertension

      Washington, District of Columbia
      This trial is testing a medication called sotatercept to see if it is safe and how it acts in children with high blood pressure in the lungs, who are already on standard treatments. The study will last for several months. Sotatercept has shown promise in improving exercise tolerance in adults with pulmonary arterial hypertension.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:1 - 17

      Key Eligibility Criteria

      Disqualifiers:Left-sided Heart Disease, Eisenmenger Syndrome, Pulmonary Veno-occlusive Diseases, Coronary Disease, Others
      Must Be Taking:PDE5 Inhibitors, ERAs, SGCS, Prostanoids

      42 Participants Needed

      Sotatercept for Pulmonary Arterial Hypertension

      Washington, District of Columbia
      This trial is testing sotatercept added to current treatments for patients with severe PAH who are at high risk of death. The goal is to see if it can lower lung blood pressure and improve patient outcomes. Sotatercept, which modulates bone morphogenic protein receptor type 2 (BMPR2) signaling, showed promising results in earlier studies.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      172 Participants Needed

      Inhaled Vardenafil for Pulmonary Arterial Hypertension

      Rochester, Minnesota
      This trial is testing an inhaled medication called RT234. It aims to help people with pulmonary arterial hypertension (PAH) breathe better and exercise more easily. The medication works by widening the blood vessels in the lungs, making it easier for the heart to pump blood. RT234 is being developed to improve exercise tolerance and symptoms in patients with PAH.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      42 Participants Needed

      Selexipag for Pulmonary Arterial Hypertension

      Washington, District of Columbia
      The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2 - 17

      Key Eligibility Criteria

      Disqualifiers:Eisenmenger Syndrome, Life Expectancy <12 Months, Others
      Must Be Taking:Endothelin Antagonists, PDE-5 Inhibitors

      138 Participants Needed

      Ralinepag for Pulmonary Arterial Hypertension

      Baltimore, Maryland
      This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Liver Disease, Renal Insufficiency, Malignancy, Others
      Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors

      1000 Participants Needed

      Ralinepag for Pulmonary Arterial Hypertension

      Baltimore, Maryland
      This trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Transplant, Others

      1000 Participants Needed

      Empagliflozin for Pulmonary Arterial Hypertension

      Baltimore, Maryland
      Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Renal Failure, Others
      Must Be Taking:PAH-targeted Therapy

      78 Participants Needed

      Sotatercept for Pulmonary Arterial Hypertension

      Baltimore, Maryland
      This trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      444 Participants Needed

      Mono vs Dual Therapy for Pediatric Pulmonary Hypertension

      Baltimore, Maryland
      The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:3 - 18

      Key Eligibility Criteria

      Disqualifiers:Syncope, RV Failure, Pregnancy, Others
      Must Not Be Taking:Cyclosporine, Glyburide, CYP3A Inhibitors, Others

      100 Participants Needed

      Oral Ifetroban for Scleroderma

      Baltimore, Maryland
      This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Lung Disease, Kidney Disease, Others
      Must Be Taking:Oral PAH Therapy

      34 Participants Needed

      High-Dose Macitentan for PAH

      Wynnewood, Pennsylvania
      This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Obesity, Diabetes, Hypertension, Coronary Artery Disease, Others

      935 Participants Needed

      Treprostinil for Pulmonary Arterial Hypertension

      Philadelphia, Pennsylvania
      The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Amphetamine Use, Hepatic Impairment, Others
      Must Be Taking:Endothelin Antagonists, PDE-5 Inhibitors

      52 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Pulmonary Arterial Hypertension Trial

      Low-Resistance Training for Pulmonary Hypertension

      Philadelphia, Pennsylvania
      The purpose of the study is to learn more about how low-resistance training impacts frailty and the quality of life of people with pulmonary arterial hypertension (PAH). Low-resistance training is an evidence-based approach that may help patients improve their functional ability.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:WHO Class IV, COPD, Others
      Must Be Taking:PAH Therapy

      20 Participants Needed

      L606 Inhalation Suspension for Pulmonary Arterial Hypertension

      Pittsburgh, Pennsylvania
      This trial tests a new medication called L606 in patients with specific types of lung disease. It aims to see if L606 is safe, helps patients breathe better, and improves their quality of life compared to an existing treatment called Tyvaso. LIQ861 is a novel dry-powder formulation of treprostinil, similar to the inhaled, nebulized treprostinil (Tyvaso®).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Sleep Apnea, Left-sided Heart Disease, Others

      28 Participants Needed

      PET Imaging for Pulmonary Arterial Hypertension

      Pittsburgh, Pennsylvania
      This trial uses a special PET scan with a tracer called 18F-FGln to study how a substance called glutamine is taken up in the lungs and heart of patients with different types of pulmonary arterial hypertension (PAH). The goal is to see if this method can help detect early stages of PAH and understand its progression. The study includes patients with various forms of PAH and healthy individuals for comparison.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Smoking, Pregnancy, Heart Conditions, Others

      71 Participants Needed

      Personalized Pain Management for Spinal Fusion

      Pittsburgh, Pennsylvania
      The purpose of this collaborative CTSA application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in children undergoing painful surgery.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:10 - 21

      Key Eligibility Criteria

      Disqualifiers:Serious Illness, Preoperative Severe Pain, Others
      Must Be Taking:Opioids

      300 Participants Needed

      Treprostinil Palmitil for PAH

      New York, New York
      The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Thromboembolic Disease, COVID-19, Others
      Must Not Be Taking:Parenteral Prostacyclin Analogues

      91 Participants Needed

      Treprostinil Palmitil for Pulmonary Arterial Hypertension

      New York, New York
      This trial is testing an inhalable medicine called TPIP to see if it can help people with high blood pressure in their lungs by making it easier for blood to flow through their lung arteries.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      102 Participants Needed

      GB002 for Pulmonary Arterial Hypertension

      New York, New York
      This trial will study the long-term effects of GB002 (seralutinib) in patients who were part of an earlier study for Pulmonary Arterial Hypertension (PAH). Seralutinib is a new treatment developed for PAH and has shown better results compared to another treatment in early studies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Heart Disease, Infections, Others
      Must Be Taking:PAH Therapies

      100 Participants Needed

      Aria CV System for Pulmonary Arterial Hypertension

      New York, New York
      This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Renal Insufficiency, Scleroderma, Others
      Must Be Taking:PH Specific Medications

      30 Participants Needed

      129 Xenon MRI for Pulmonary Arterial Hypertension

      Durham, North Carolina
      The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:PH Other Than IPAH Or PAH-CTD, Others

      20 Participants Needed

      Xenon MRI for Pulmonary Arterial Hypertension

      Durham, North Carolina
      This trial uses a special MRI scan with a gas to monitor lung function in patients with severe lung disease. It targets those being monitored over time to better understand and track their condition. The MRI technique provides detailed lung function measurements and is well-tolerated, allowing for thorough exploration of lung function.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Cancer, Sickle Cell, Others

      60 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Pulmonary Arterial Hypertension clinical trials pay?
      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
      How do Pulmonary Arterial Hypertension clinical trials work?
      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Pulmonary Arterial Hypertension trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Pulmonary Arterial Hypertension is 12 months.
      How do I participate in a study as a "healthy volunteer"?
      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
      What does the "phase" of a clinical trial mean?
      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
      Do I need to be insured to participate in a Pulmonary Arterial Hypertension medical study ?
      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
      What are the newest Pulmonary Arterial Hypertension clinical trials ?
      Most recently, we added Empagliflozin for Pulmonary Arterial Hypertension, 129Xe Imaging for Pulmonary Arterial Hypertension and Sotatercept for Pulmonary Arterial Hypertension to the Power online platform.